佐剂RSV预融合F3疫苗预防心血管事件及慢阻肺哮喘急性加重
一项回顾性队列研究利用美国Optum数据库索赔数据,评估佐剂RSVPreF3疫苗在≥60岁有基础心血管病、慢阻肺和哮喘人群中预防主要不良心血管事件(MACE)及严重急性加重的真实世界疫苗有效性(VE)。接种组与未接种组按1:4匹配,结果显示对RSV相关MACE的VE为65.0%(含死亡)和63.1%(不含死亡),对RSV相关慢阻肺严重急性加重VE为74.4%,对RSV相关哮喘严重急性加重VE为61.6%。
要点
- 在有心血管病的≥60岁人群中,佐剂RSVPreF3疫苗对RSV相关MACE的VE为65.0%(95%CI 45.4%-77.6%)。
- 在有慢阻肺人群中,对RSV相关慢阻肺严重急性加重的VE为74.4%(95%CI 59.3%-83.9%)。
- 在有哮喘人群中,对RSV相关哮喘严重急性加重的VE为61.6%(95%CI 9.1%-83.7%)。
核心结论
- 佐剂RSVPreF3疫苗接种可能对有基础心血管病、慢阻肺和哮喘的≥60岁人群提供针对RSV相关MACE及严重急性加重的显著保护。
研究设计与样本
- 采用Optum研究数据库索赔数据的回顾性队列研究。
- 接种与未接种的≥60岁成人按年龄、性别、保险和州以1:4匹配,基线特征通过倾向评分加权平衡。
- 基线有心血管病者接种170803例、未接种699177例;有慢阻肺者接种76209例、未接种286406例;有哮喘者接种53636例、未接种190590例。
- 从索引日期后14天随访至退保、死亡、接种任何RSV疫苗或分析期结束(2024年5月31日),用Cox回归估计风险比并计算VE。
主要发现
- 有心血管病人群中,含死亡的RSV相关MACE的VE为65.0%(95%CI 45.4%-77.6%)。
- 有心血管病人群中,不含死亡的RSV相关MACE的VE为63.1%(95%CI 41.8%-76.6%)。
- 有慢阻肺人群中,RSV相关慢阻肺严重急性加重的VE为74.4%(95%CI 59.3%-83.9%)。
- 有哮喘人群中,RSV相关哮喘严重急性加重的VE为61.6%(95%CI 9.1%-83.7%)。
临床怎么用
- 对≥60岁有心血管病、慢阻肺或哮喘的患者,可考虑接种佐剂RSVPreF3疫苗以降低RSV相关MACE及严重急性加重风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies have demonstrated real-world vaccine effectiveness (VE) of adjuvanted respiratory syncytial virus (RSV) prefusion F3 (RSVPreF3) vaccination against RSV-related hospitalizations among older adults. RESEARCH QUESTION: What is the VE of adjuvanted RSVPreF3 vaccination against major adverse cardiovascular events (MACEs), severe COPD exacerbations, and severe asthma exacerbations among US adults ≥ 60 years of age with underlying cardiovascular disease (CVD), COPD, and asthma, respectively? STUDY DESIGN AND METHODS: A retrospective cohort study using Optum Research Database claims data assessed adjuvanted RSVPreF3 VE against MACE and against severe exacerbations of COPD and asthma (overall and RSV related) among populations with baseline CVD, COPD, and asthma, respectively. Between August 2023 and May 2024, vaccinated and unvaccinated adults ≥ 60 years of age were matched 1:4 on age, sex, insurance, and US state. Index date for vaccinated and matched unvaccinated patients was the same, assigned as vaccination date, with baseline characteristics assessed during 12 months before index and balanced via propensity score-based weighting. Outcomes were assessed 14 days after index to disenrollment, death, receipt of any RSV vaccination, or end of analysis period (May 31, 2024). Cox proportional hazards regression estimated hazard ratios within baseline disease populations, with VE calculated as (1 - hazard ratio) × 100%. RESULTS: At baseline, 170,803 vaccinated and 699,177 unvaccinated individuals had CVD, 76,209 vaccinated and 286,406 unvaccinated individuals had COPD, and 53,636 vaccinated and 190,590 unvaccinated individuals had asthma. Among individuals with CVD, estimated VE was 65.0% (95% CI, 45.4%-77.6%) against RSV-related MACEs including mortality and 63.1% (95% CI, 41.8%-76.6%) against RSV-related MACEs not including mortality. Among individuals with COPD, VE was 74.4% (95% CI, 59.3%-83.9%) against RSV-related severe COPD exacerbations. In individuals with asthma, VE against RSV-related severe asthma exacerbations was 61.6% (95% CI, 9.1%-83.7%). INTERPRETATION: Our results show that adjuvanted RSVPreF3 vaccination may offer considerable protection against RSV-related MACEs and severe COPD and asthma exacerbation events in individuals with underlying CVD, COPD, and asthma.
引用
- Singer, Steffens, La, et al. Effectiveness of the Adjuvanted Respiratory Syncytial Virus Prefusion F3 Vaccine in Preventing Major Adverse Cardiovascular Events and Severe Exacerbations of COPD and Asthma Among US Adults ≥ 60 Years of Age. Chest. 2026. PMID: 42492842. doi:10.1016/j.chest.2026.06.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。